文献速递重症综合管理与镇静镇痛儿科与产科急症

欧洲儿科重症监护病房疼痛与镇静管理与监测:一项ESPNIC调查

Pain and sedation management and monitoring in pediatric intensive care units across Europe: an ESPNIC survey.
PubMed 文献 · Crit Care · 2022-03-31
一句话结论欧洲27国215个PICU调查显示:71%使用镇痛镇静方案,首选芬太尼联合咪达唑仑,但起始剂量与评估工具差异很大

该ESPNIC调查于2021年1—4月向欧洲357个PICU发放在线问卷,评估镇痛镇静的药物选择、剂量及监测工具使用情况,并比较高容量与低容量PICU的实践差异。共215个PICU(应答率60%)来自27个欧洲国家完成应答。71%的PICU报告使用镇痛镇静管理方案,高容量PICU使用比例更高(77% vs 63%,p=0.028)。首选药物组合为阿片类联合苯二氮䓬类,最常用芬太尼(51%)和咪达唑仑(71%),但起始剂量差异很大:芬太尼0.1—5 mcg/kg/h,咪达唑仑0.01—0.5 mg/kg/h。大多数PICU每日评估并记录疼痛(81%)和镇静(87%),分别首选经验证的FLACC量表(54%)和COMFORT行为量表(48%),监测主要由护士完成(分别为92%和84%)。86%的PICU在某些场景使用神经肌肉阻滞剂,瘫痪患者的监测首选借助电子设备观察生命体征。作者认为需要进一步研究和制定循证指南以优化药物剂量及镇痛镇静评估。

要点

  • 71%的欧洲PICU使用镇痛镇静管理方案,高容量PICU使用更频繁(77% vs 63%,p=0.028)
  • 首选药物组合为阿片类联合苯二氮䓬类:芬太尼51%、咪达唑仑71%为最常用药物
  • 起始剂量差异大:芬太尼0.1—5 mcg/kg/h,咪达唑仑0.01—0.5 mg/kg/h
  • 81%的PICU每日评估并记录疼痛,首选FLACC量表(54%);87%每日评估镇静,首选COMFORT行为量表(48%)
  • 疼痛与镇静监测主要由护士完成(分别为92%和84%);86%的PICU在某些场景使用神经肌肉阻滞剂,瘫痪患者监测首选借助电子设备观察生命体征

适用人群与场景

  • 欧洲27个国家的215个PICU(共向357个PICU发放问卷,应答率60%)
  • 调查对象为PICU的镇痛镇静管理与监测实践,未限定患儿病种或病情阶段

处置流程与药物剂量

  • 71%的PICU报告使用镇痛镇静管理方案,高容量PICU为77% vs 低容量PICU 63%(p=0.028)
  • 首选药物组合为阿片类联合苯二氮䓬类,最常用芬太尼(51%)和咪达唑仑(71%)
  • 芬太尼起始剂量范围为0.1—5 mcg/kg/h,咪达唑仑起始剂量范围为0.01—0.5 mg/kg/h,各PICU之间差异很大
  • 81%的PICU每日评估并记录疼痛,首选经验证的FLACC量表(54%);87%的PICU每日评估并记录镇静,首选COMFORT行为量表(48%)
  • 疼痛监测主要由护士完成(92%),镇静监测主要由护士完成(84%)
  • 86%的应答PICU在某些场景使用神经肌肉阻滞剂,瘫痪患者的监测首选借助电子设备观察生命体征

研究设计与关键结果

  • 研究类型:ESPNIC在线问卷调查,向欧洲357个PICU发放问卷,应答215个(应答率60%),来自27个欧洲国家,调查时间为2021年1月至4月
  • 71%的PICU使用镇痛镇静管理方案,高容量PICU使用比例高于低容量PICU(77% vs 63%,p=0.028)
  • 首选药物组合为阿片类联合苯二氮䓬类:芬太尼51%、咪达唑仑71%为最常用药物
  • 起始剂量差异:芬太尼0.1—5 mcg/kg/h,咪达唑仑0.01—0.5 mg/kg/h
  • 81%的PICU每日评估并记录疼痛,首选FLACC量表(54%);87%每日评估并记录镇静,首选COMFORT行为量表(48%)
  • 疼痛与镇静监测主要由护士完成(分别为92%和84%)
  • 86%的PICU在某些场景使用神经肌肉阻滞剂,瘫痪患者监测首选借助电子设备观察生命体征

证据类型、等级与局限

  • 证据类型:ESPNIC问卷调查(横断面调查)
  • 局限:作者指出需要进一步研究和制定循证指南以优化药物剂量及镇痛镇静评估

对床旁实践的改变

  • 调查显示欧洲PICU的镇痛镇静药物选择、剂量和评估策略差异很大,作者认为需要进一步研究和制定循证指南以优化药物剂量及镇痛镇静评估

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Management and monitoring of pain and sedation to reduce discomfort as well as side effects, such as over- and under-sedation, withdrawal syndrome and delirium, is an integral part of pediatric intensive care practice. However, the current state of management and monitoring of analgosedation across European pediatric intensive care units (PICUs) remains unknown. The aim of this survey was to describe current practices across European PICUs regarding the management and monitoring of pain and sedation.

METHODS: An online survey was distributed among 357 European PICUs assessing demographic features, drug choices and dosing, as well as usage of instruments for monitoring pain and sedation. We also compared low- and high-volume PICUs practices. Responses were collected from January to April 2021.

RESULTS: A total of 215 (60% response rate) PICUs from 27 European countries responded. Seventy-one percent of PICUs stated to use protocols for analgosedation management, more frequently in high-volume PICUs (77% vs 63%, p = 0.028). First-choice drug combination was an opioid with a benzodiazepine, namely fentanyl (51%) and midazolam (71%) being the preferred drugs. The starting doses differed between PICUs from 0.1 to 5 mcg/kg/h for fentanyl, and 0.01 to 0.5 mg/kg/h for midazolam. Daily assessment and documentation for pain (81%) and sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC scale (54%) and the COMFORT Behavioural scale (48%), respectively. Both analgesia and sedation were mainly monitored by nurses (92% and 84%, respectively). Eighty-six percent of the responding PICUs stated to use neuromuscular blocking agents in some scenarios. Monitoring of paralysed patients was preferably done by observation of vital signs with electronic devices support.

CONCLUSIONS: This survey provides an overview of current analgosedation practices among European PICUs. Drugs of choice, dosing and assessment strategies were shown to differ widely. Further research and development of evidence-based guidelines for optimal drug dosing and analgosedation assessment are needed.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Daverio M, von Borell F, Ramelet AS, et al. Pain and sedation management and monitoring in pediatric intensive care units across Europe: an ESPNIC survey. Crit Care. 2022. PMID: 35361254. doi:10.1186/s13054-022-03957-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。